Dr. Loeb's practice focuses on biotechnology trial work and litigation and strategic patent counseling. To achieve his clients' strategic goals, Dr. Loeb melds the technical expertise gained in more than 10 years as a bench scientist and teacher with his deep experience in all aspects of high-stakes biotech, pharmaceutical, and medical device patent litigation.
Since joining Day Casebeer in 1999, Dr. Loeb has litigated patent disputes before U.S. District Courts, the International Trade Commission, and the Federal Circuit Court of Appeals. Dr. Loeb also represents clients in reexamination proceedings before the U.S. Patent Office, and has provided advice in patent revocation and infringement actions in various foreign jurisdictions.
Before attending Stanford Law School, Dr. Loeb obtained his Ph.D. in Biology from the Massachusetts Institute of Technology. At M.I.T., Dr. Loeb worked at the Whitehead Institute for Biomedical Research with its then Director, Professor Gerald R. Fink. Jonathan's doctoral research concerned the genetics and cell biology of the Nuclear Pore Complex in Saccharomyces cerevisiae. After receiving his Ph.D., Dr. Loeb did post-doctoral research at M.I.T. and the University of California, Irvine, focusing on the pathogenesis of fungi that afflict immunocompromised individuals. Dr. Loeb is lead author of a number of scientific papers in peer-reviewed biology journals.
REPRESENTATIVE ENGAGEMENTS
- Amgen v. Roche, (U.S. Dist. Court Mass. and Fed. Cir.)
Trial and appellate counsel for Amgen in patent infringement suit involving recombinant erythropoietin. Case was tried to a verdict in a four-week jury and bench trial in Amgen's favor (appeal pending).
- SRI International v. ISS, Inc. and Symantec, Inc. (U.S. Dist. Court Del.)
Counsel for Symantec Inc. in patent infringement action involving network intrusion detection systems. Currently scheduled for trial in September, 2008.
- In the Matter of Certain Products and Pharmaceutical Compositions Containing Recombinant Human Erythropoietin, (U.S. International Trade Commission)
Trial counsel for Amgen in ITC investigation regarding the exclusion from importation into the U.S. of Roche's Mircera® product (appeal in Amgen's favor).
- Boston Scientific v. Cook, (U.S. Dist. Court Ill. and Seventh Cir.)
Counsel for Angiotech in dispute between licensees regarding license rights to paclitaxel stents (favorably resolved).
- Pfizer v. Lilly ICOS LLC, et al., (U.S. Dist. Court Del. and U.S. Patent Office)
Trial counsel for Lilly ICOS and ICOS Pharmaceuticals in patent infringement action involving phosphodiesterase-5 inhibitors, Cialis® and Viagra® (reexamination resolved in Lilly ICOS and ICOSs favor).
- Amgen v. Hoechst Marion Roussel (Aventis) and Transkaryotic Therapies (TKT), (U.S. Dist. Court Mass. and Fed. Cir.)
Trial and appellate counsel for Amgen in patent infringement suit involving recombinant erythropoietin. A seven-week trial and subsequent three-week re-trial resulted judgments in Amgens favor (appeal pending).
- Biogen v. Amgen, (U.S. Dist. Court Mass.)
Trial counsel for Amgen in infringement action involving Amgen's recombinant granulocyte colony stimulating factor product (Neupogen®) (summary judgment in Amgens favor).
EDUCATION
A.B., high honors, University of California, Berkeley (1987)
Ph.D., Massachusetts Institute of Technology (1995)
J.D., Stanford Law School (2000)
BAR ADMISSIONS AND MEMBERSHIPS
All State Courts of California
U.S. District Court for the Northern District of California
U.S. Court of Appeals for the Federal Circuit
U.S. Patent and Trademark Office